Jul292021 Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease July 29, 2021
Jun282021 Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia June 28, 2021
Jun242021 Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering June 24, 2021
Jun212021 Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome June 21, 2021
Jun142021 Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer’s Disease June 14, 2021
Jun82021 Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease June 8, 2021
Jun32021 Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73 (blarcamesine) for the Treatment of Cardiac Dysfunctions June 3, 2021
May262021 Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors May 26, 2021
May132021 Anavex Life Sciences Reports Fiscal 2021 Second Quarter Financial Results And Business Outlook May 13, 2021
May72021 Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit May 7, 2021
May62021 Anavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021 May 6, 2021
